Vibostolimab/Pembrolizumab

Phase 2

15%

Phase 2

Development Phase

1

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

Upcoming Catalysts

May 31

MRK$245.9BPhase 2

Vibostolimab/Pembrolizumab Phase 2 Results Expected

Vibostolimab/Pembrolizumab • Carcinoma, Renal Cell

Drug Information

Target Indication

Carcinoma, Renal Cell

Clinical Trial

Last updated: 12/17/2025

Developer

MRK

MERCK

Related Pipeline

Renal Cell Carcinoma

Mesothelioma

Psoriasis

Metastatic Esophageal Squamous Cell Carcinoma

Colorectal Neoplasms